Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618046 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT00618046 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 48 participants.
The verdict
NCT00618046, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
The objective of this study was to assess bioequivalence of a potential generic 600 mb oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg dose, administered with food.
Interventions
- DRUG Oxcarbazepine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-11 |
| Est. Completion | 2004-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618046
The ClinicalTrials.gov registry entry for NCT00618046 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxcarbazepine is the first listed.
NCT00618046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618046 about?
NCT00618046 is a clinical study titled "Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions". The objective of this study was to assess bioequivalence of a potential generic 600 mb oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg dose, administered with food.
What is the current status of trial NCT00618046?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2004-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00618046?
The interventions under investigation include: Oxcarbazepine (DRUG).
Who is sponsoring clinical trial NCT00618046?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.